As the COVID-19 pandemic spreads throughout the United States and Americans anxiously await the arrival of a vaccine, biotech companies are grappling with the uncertainty of patent protection for COVID related biomedical...more
9/15/2020
/ Biomedical Advanced Research and Development Authority (BARDA) ,
Centers for Disease Control and Prevention (CDC) ,
Collaboration ,
Coronavirus/COVID-19 ,
Department of Health and Human Services (HHS) ,
Eligibility ,
Food and Drug Administration (FDA) ,
Intellectual Property Protection ,
National Institute of Health (NIH) ,
OSTP ,
Patent Act ,
Patents ,
Policy Drafting ,
Section 101 ,
Trade Secrets ,
Transparency
As the world grapples with its response to COVID-19, the availability and nature of intellectual property protection afforded for diagnostic tests, treatments, vaccines, and accompanying data is likely to have a significant...more